{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:03Z","timestamp":1787003463564,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Struct Mol Biol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41594-026-01820-9","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:03:26Z","timestamp":1782378206000},"page":"1086-1096","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Structurally defining neurokinin selectivity to improve NK2R agonists"],"prefix":"10.1038","volume":"33","author":[{"given":"Artem","family":"Pavlovskyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5096-2609","authenticated-orcid":false,"given":"Mar\u00eda","family":"Gestal-Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1216-7521","authenticated-orcid":false,"given":"Ole H.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thue W.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2981-4991","authenticated-orcid":false,"given":"Zachary","family":"Gerhart-Hines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3178-9238","authenticated-orcid":false,"given":"Xiangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"1820_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00337-8","author":"TD M\u00fcller","year":"2021","unstructured":"M\u00fcller, T. D., Bl\u00fcher, M., Tsch\u00f6p, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-021-00337-8 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1820_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-025-01343-5","author":"C Clemmensen","year":"2025","unstructured":"Clemmensen, C., Gerhart-Hines, Z., Schwartz, T. W., Zierath, J. R. & Sakamoto, K. Shaping the future of cardiometabolic innovation: advances and opportunities. Nat. Metab. https:\/\/doi.org\/10.1038\/s42255-025-01343-5 (2025).","journal-title":"Nat. Metab."},{"key":"1820_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1820_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies, M. et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 397, 971\u2013984 (2021).","journal-title":"Lancet Lond. Engl."},{"key":"1820_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey, W. T. et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N. Engl. J. Med. 393, 635\u2013647 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1820_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies, M. J. et al. Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes. N. Engl. J. Med. 393, 648\u2013659 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1820_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1820_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402, 613\u2013626 (2023).","journal-title":"Lancet"},{"key":"1820_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/oby.23374","volume":"30","author":"B\u00d8 Christoffersen","year":"2022","unstructured":"Christoffersen, B. \u00d8 et al. Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obes. Silver Spring Md 30, 841\u2013857 (2022).","journal-title":"Obes. Silver Spring Md"},{"key":"1820_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jama.1933.02740280013006","volume":"101","author":"WC Cutting","year":"1933","unstructured":"Cutting, W. C., Mehrtens, H. G. & Tainter, M. L. Actions and uses of dinitrophenol: promising metabolic applications. J. Am. Med. Assoc. 101, 193 (1933).","journal-title":"J. Am. Med. Assoc."},{"key":"1820_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41586-024-08207-0","volume":"635","author":"F Sass","year":"2024","unstructured":"Sass, F. et al. NK2R control of energy expenditure and feeding to treat metabolic diseases. Nature 635, 987\u20131000 (2024).","journal-title":"Nature"},{"key":"1820_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41392-024-02100-y","volume":"10","author":"D Thor","year":"2025","unstructured":"Thor, D. & Pr\u00f6mel, S. Beyond incretins: targeting neurokinin receptors for obesity treatment. Signal Transduct. Target. Ther. 10, 21 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1820_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1152\/physrev.00031.2013","volume":"94","author":"MS Steinhoff","year":"2014","unstructured":"Steinhoff, M. S., von Mentzer, B., Geppetti, P., Pothoulakis, C. & Bunnett, N. W. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol. Rev. 94, 265\u2013301 (2014).","journal-title":"Physiol. Rev."},{"key":"1820_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0165-6147(97)90663-5","volume":"18","author":"CA Maggi","year":"1997","unstructured":"Maggi, C. A. & Schwartz, T. W. The dual nature of the tachykinin NK1 receptor. Trends Pharmacol. Sci. 18, 351\u2013355 (1997).","journal-title":"Trends Pharmacol. Sci."},{"key":"1820_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0167-0115(95)00019-8","volume":"57","author":"U Holzer-Petsche","year":"1995","unstructured":"Holzer-Petsche, U. Tachykinin receptors in gastrointestinal motility. Regul. Pept. 57, 19\u201342 (1995).","journal-title":"Regul. Pept."},{"key":"1820_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1582-4934.2006.tb00288.x","volume":"10","author":"M Faussone-Pellegrini","year":"2006","unstructured":"Faussone-Pellegrini, M. Relationships between neurokinin receptor-expressing interstitial cells of Cajal and tachykininergic nerves in the gut. J. Cell. Mol. Med. 10, 20\u201332 (2006).","journal-title":"J. Cell. Mol. Med."},{"key":"1820_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2165\/00023210-200519040-00001","volume":"19","author":"I Herpfer","year":"2005","unstructured":"Herpfer, I. & Lieb, K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs 19, 275\u2013293 (2005).","journal-title":"CNS Drugs"},{"key":"1820_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/13543776.2020.1769599","volume":"30","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz, M. & Cove\u00f1as, R. Neurokinin receptor antagonism: a patent review (2014\u2013present). Expert Opin. Ther. Pat. 30, 527\u2013539 (2020).","journal-title":"Expert Opin. Ther. Pat."},{"key":"1820_CR19","doi-asserted-by":"publisher","first-page":"663535","DOI":"10.3389\/fcell.2021.663535","volume":"9","author":"GF Pav\u00f3n-Romero","year":"2021","unstructured":"Pav\u00f3n-Romero, G. F., Serrano-P\u00e9rez, N. H., Garc\u00eda-S\u00e1nchez, L., Ram\u00edrez-Jim\u00e9nez, F. & Ter\u00e1n, L. M. Neuroimmune pathophysiology in asthma. Front. Cell Dev. Biol. 9, 663535 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1820_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev.ne.11.030188.000305","volume":"11","author":"JE Maggio","year":"1988","unstructured":"Maggio, J. E. Tachykinins. Annu. Rev. Neurosci. 11, 13\u201328 (1988).","journal-title":"Annu. Rev. Neurosci."},{"key":"1820_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk2872","volume":"7","author":"C Thom","year":"2021","unstructured":"Thom, C. et al. Structures of neurokinin 1 receptor in complex with Gq and Gs proteins reveal substance P binding mode and unique activation features. Sci. Adv. 7, eabk2872 (2021).","journal-title":"Sci. Adv."},{"key":"1820_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41589-021-00890-8","volume":"18","author":"JA Harris","year":"2022","unstructured":"Harris, J. A. et al. Selective G protein signaling driven by substance P\u2013neurokinin receptor dynamics. Nat. Chem. Biol. 18, 109\u2013115 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1820_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41592-023-02082-9","volume":"21","author":"M Chen","year":"2024","unstructured":"Chen, M., Schmid, M. F. & Chiu, W. Improving resolution and resolvability of single-particle cryoEM structures using Gaussian mixture models. Nat. Methods 21, 37\u201340 (2024).","journal-title":"Nat. Methods"},{"key":"1820_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41421-022-00437-8","volume":"8","author":"W Sun","year":"2022","unstructured":"Sun, W. et al. Structural insights into the activation of neurokinin 2 receptor by neurokinin A. Cell Discov. 8, 72 (2022).","journal-title":"Cell Discov."},{"key":"1820_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0143-4179(91)90137-8","volume":"19","author":"G Chassaing","year":"1991","unstructured":"Chassaing, G. et al. Selective agonists of NK-2 binding sites highly active on rat portal vein (NK-3 bioassay). Neuropeptides 19, 91\u201395 (1991).","journal-title":"Neuropeptides"},{"key":"1820_CR26","doi-asserted-by":"publisher","first-page":"e0175642","DOI":"10.1371\/journal.pone.0175642","volume":"12","author":"R Nehm\u00e9","year":"2017","unstructured":"Nehm\u00e9, R. et al. Mini-G proteins: novel tools for studying GPCRs in their active conformation. PLoS ONE 12, e0175642 (2017).","journal-title":"PLoS ONE"},{"key":"1820_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature18966","volume":"536","author":"B Carpenter","year":"2016","unstructured":"Carpenter, B., Nehm\u00e9, R., Warne, T., Leslie, A. G. W. & Tate, C. G. Structure of the adenosine A(2A) receptor bound to an engineered G protein. Nature 536, 104\u2013107 (2016).","journal-title":"Nature"},{"key":"1820_CR28","first-page":"583","volume":"29","author":"B Carpenter","year":"2016","unstructured":"Carpenter, B. & Tate, C. G. Engineering a minimal G protein to facilitate crystallisation of G protein-coupled receptors in their active conformation. Protein Eng. Des. Sel. 29, 583\u2013594 (2016).","journal-title":"Protein Eng. Des. Sel."},{"key":"1820_CR29","doi-asserted-by":"publisher","first-page":"105438","DOI":"10.1016\/j.jbc.2023.105438","volume":"299","author":"JJ Madsen","year":"2023","unstructured":"Madsen, J. J. et al. Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors. J. Biol. Chem. 299, 105438 (2023).","journal-title":"J. Biol. Chem."},{"key":"1820_CR30","doi-asserted-by":"publisher","first-page":"108522","DOI":"10.1016\/j.jbc.2025.108522","volume":"301","author":"JE Petersen","year":"2025","unstructured":"Petersen, J. E. et al. Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides. J. Biol. Chem. 301, 108522 (2025).","journal-title":"J. Biol. Chem."},{"key":"1820_CR31","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.1073\/pnas.1812717115","volume":"115","author":"J Yin","year":"2018","unstructured":"Yin, J. et al. Crystal structure of the human NK1 tachykinin receptor. Proc. Natl Acad. Sci. USA 115, 13264\u201313269 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1820_CR32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/ar8000603","volume":"41","author":"J Chatterjee","year":"2008","unstructured":"Chatterjee, J., Gilon, C., Hoffman, A. & Kessler, H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc. Chem. Res. 41, 1331\u20131342 (2008).","journal-title":"Acc. Chem. Res."},{"key":"1820_CR33","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/bip.21057","volume":"90","author":"Y Linde","year":"2008","unstructured":"Linde, Y. et al. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers 90, 671\u2013682 (2008).","journal-title":"Biopolymers"},{"key":"1820_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/psc.3242","volume":"26","author":"NM Grob","year":"2020","unstructured":"Grob, N. M., Behe, M., von Guggenberg, E., Schibli, R. & Mindt, T. L. Corrigendum concerning \u2018Methoxinine\u2014an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates\u2019. J. Pept. Sci. 26, e3242 (2020).","journal-title":"J. Pept. Sci."},{"key":"1820_CR35","doi-asserted-by":"publisher","first-page":"107948","DOI":"10.1016\/j.jbc.2024.107948","volume":"300","author":"JE Petersen","year":"2024","unstructured":"Petersen, J. E. et al. Molecular determinants of neuropeptide-mediated activation mechanisms in tachykinin NK1 and NK2 receptors. J. Biol. Chem. 300, 107948 (2024).","journal-title":"J. Biol. Chem."},{"key":"1820_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"JS Lorente","year":"2025","unstructured":"Lorente, J. S. et al. GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 24, 458\u2013479 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1820_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s43556-023-00156-w","volume":"4","author":"L Cheng","year":"2023","unstructured":"Cheng, L. et al. Structure, function and drug discovery of GPCR signaling. Mol. Biomed. 4, 46 (2023).","journal-title":"Mol. Biomed."}],"container-title":["Nature Structural & Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01820-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01820-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:37:35Z","timestamp":1784129855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41594-026-01820-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1038\/s41594-026-01820-9","relation":{},"ISSN":["1545-9993","1545-9985"],"issn-type":[{"value":"1545-9993","type":"print"},{"value":"1545-9985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.W.S. and Z.G.-H. are cofounders of Embark Laboratories ApS and Incipiam Pharma ApS, which are both companies developing therapeutics for the treatment of diabetes and obesity. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}